Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Single stranded DNA binding protein 3 (SSBP3) is a nuclear protein predicted to bind single-stranded DNA and act as a transcription coactivator[4]. It is involved in the regulation of gene expression, particularly in promoting transcription by RNA polymerase II, and may play a role in hematopoietic progenitor cell differentiation[4]. SSBP3 contains domains such as a lissencephaly type-1-like homology (LisH) motif and a proline-rich domain, which are conserved across species[2]. Mutations or dosage alterations of SSBP3 are implicated in neurodevelopmental disorders, and 1p32.3 microdeletion/duplication syndromes, with effects potentially including intellectual disability, developmental delay, and autism-like behaviors[2]. SSBP3 may be involved in transcriptional regulation through binding single-stranded polypyrimidine sequences in promoters, such as in the alpha 2(I) collagen gene[4]. Human SSBP3 has no reported established role as a therapeutic target, and there are currently no approved drugs known to directly interact with SSBP3[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Single stranded DNA binding protein 3 (SSBP3).